Shanghai Junshi Biosciences Co., Ltd. (688180.SS) SHH

Currency In CNY

Key Executives

Name	Title	Pay	Year Born
Cong Li	Co-CEO & Executive Director	1.78M	1964
Jianjun Zou	GM, Chief Executive Officer & Executive Director	9.9M	1971
Xin Li	Senior Vice President of Government Affairs & Executive Director	2.37M	1979
Sheng Yao	Deputy GM, Senior Vice President & Executive Director	2.94M	1975
Zhuobing Zhang	Deputy GM & Executive Director	3.53M	1967
Ning Li	Executive Vice-Chairman of the Board	3.6M	1961
Jun Xiong	Executive Chairman	3.91M	1974
Gang Wang	Chief Quality Officer, Senior VP of Industry Affairs & Executive Director	4.98M	1957
Zhengyu Wang	Joint Company Secretary	0	1995
Baohong Xu	Chief Financial Officer	0	1979

Name

Title

Pay

Year Born

Cong Li

Co-CEO & Executive Director

1.78M

1964

Jianjun Zou

GM, Chief Executive Officer & Executive Director

9.9M

1971

Xin Li

Senior Vice President of Government Affairs & Executive Director

2.37M

1979

Sheng Yao

Deputy GM, Senior Vice President & Executive Director

2.94M

1975

Zhuobing Zhang

Deputy GM & Executive Director

3.53M

1967

Ning Li

Executive Vice-Chairman of the Board

3.6M

1961

Jun Xiong

Executive Chairman

3.91M

1974

Gang Wang

Chief Quality Officer, Senior VP of Industry Affairs & Executive Director

4.98M

1957

Zhengyu Wang

Joint Company Secretary

1995

Baohong Xu

Chief Financial Officer

1979

Description

Shanghai Junshi Biosciences Co., Ltd. is a biopharmaceutical enterprise dedicated to the research, development, and marketing of innovative therapeutic agents. Operating within the People's Republic of China, their focus spans critical medical areas such as oncology, metabolic diseases, autoimmune disorders, neurological conditions, and infectious diseases. Among its principal offerings is JS001, commercialized as TUOYI. This recombinant humanized anti-PD-1 monoclonal antibody has received approval for a broad spectrum of cancer indications, including various forms of melanoma, soft tissue sarcoma, nasopharyngeal carcinoma, urothelial carcinoma, non-small cell lung carcinoma, triple-negative breast carcinoma, esophageal squamous cell carcinoma, and hepatocellular carcinoma. Beyond TUOYI, Junshi Biosciences boasts a robust pipeline of investigational drugs. These include UBP1211, a biosimilar of Humira, targeting conditions like rheumatoid arthritis, ankylosing spondylitis, and psoriasis; JS002, a recombinant humanized anti-PCSK9 monoclonal antibody aimed at hyperlipidemia; and UBP1213, a recombinant humanized anti-BLyS monoclonal antibody in injectable form. Further developments encompass JS501, a biosimilar to Avastin; JS003, a recombinant humanized anti-PD-L1 monoclonal antibody for injection; JS101, identified as a pan-CDK inhibitor; TAB004/JS004, a recombinant humanized anti-BTLA monoclonal antibody; and JS005, a recombinant humanized anti-IL-17A monoclonal antibody for injection. The company has also established strategic collaborations. Notably, it partners with Eli Lilly and Company on the co-development of therapeutic antibodies intended for the prevention and treatment of COVID-19, the illness caused by the SARS-CoV-2 novel coronavirus. Additionally, an alliance with Coherus Biosciences, Inc. facilitates the development and commercialization of toripalimab, Junshi Biosciences' anti-PD-1 antibody. Founded in 2012, Shanghai Junshi Biosciences Co., Ltd. maintains its corporate headquarters in Shanghai, People's Republic of China.